カテゴリ： GlobalData, スイス, 企業調査

Novartis AG (NOVN)-医療機器分野：企業M&A・提携分析

◆英語タイトル：Novartis AG (NOVN) - Medical Equipment - Deals and Alliances Profile
◆商品コード：DATA8010989
◆発行会社（調査会社）：GlobalData
◆発行日：2017年12月21日
◆ページ数：211
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：スイス
◆産業分野：医療機器
◆販売価格オプション（消費税別）
Single UserUSD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Novartis AG (Novartis) is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products. It provides drugs for the treatment of cancer, cardiovascular diseases, dermatological conditions, neurological disorders, ophthalmic diseases, respiratory diseases, immune disorders and infections, among others. The company offers eye care products through its subsidiary, Alcon; and generic medicines through Sandoz. Novartis carries out research in various disease areas through The Novartis Institutes for BioMedical Research (NIBR). The company operates through a network of subsidiaries and offices in the Americas, Europe, the Middle East, Africa and Asia-Pacific. Novartis is headquartered in Basel, Switzerland.

Novartis AG (NOVN) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 7
List of Figures 8
Novartis AG, Medical Equipment, Deals By Year, 2011 to YTD 2017 10
Novartis AG, Medical Equipment Deals By Type, 2011 to YTD 2017 11
Novartis AG, Medical Equipment, Deals By Region, 2011 to YTD 2017 12
Novartis AG, Medical Equipment, Deals By Market, 2011 to YTD 2017 13
Novartis AG, Medical Equipment, Deals Summary, 2011 to YTD 2017 14
Novartis AG, Medical Equipment, Deal Details 22
Venture Financing 22
ImaginAb Raises USD7.7 Million in Venture Financing 22
Rani Therapeutics Raises USD39 Million in Series D Financing 23
Lemonaid Health Raises USD11 Million in Series A Financing 24
Atlas Genetics Raises USD35 Million in Series D Financing 25
Seventh Sense Biosystems Raises USD10 Million in Series C Financing 27
Rox Medical Raises USD40 Million in Series E Financing 29
Cota Raises Funds through Venture Financing 30
Ra Pharma Raises USD58.5 Million in Series B Financing 31
Autonomic Technologies Raises Additional USD5.5 Million in Series D Financing 32
MyoPowers Medical Raises USD5 Million in Venture Financing 34
Autonomic Technologies Raises USD38 Million in Series D Financing 35
Merganser Biotech Raises USD28 Million in Series A Financing 37
Encore Vision Raises USD1 Million in Venture Financing 38
Atlas Genetics Raises USD20 Million in Series C Financing 39
Transcend Medical Raises USD7.2 Million in Venture Financing 41
BioNano Genomics Raises USD53 Million in Series C Venture Financing 42
Seventh Sense Biosystems Raises USD16 Million in Series B Financing 43
ImaginAb Raises US$21 Million In Series B Venture Financing 45
Transcend Medical Raises US$22 Million In Series C Venture Financing 46
Wavetec Vision Systems Raises US$0.8 Million In Venture Financing 47
Encore Vision Secures USD5 Million in Venture Funding 48
Wavetec Vision Raises US$11 Million In Series D-2 Financing 49
Proteus Digital Health Raises US$63 Million In Series F Financing Round 50
Health XL Raises Funds Through Venture Financing 51
Wavetec Vision Raises US$16.5 Million In Venture Financing 52
Advanced Animal Diagnostics Secures USD4 Million in Second Tranche of Series B Funding 53
ImaginAb Raises US$12.5 Million In Series A Financing 54
WaveTec Vision Raises US$1.5 Million In Venture Financing 55
Transcend Medical Secures USD16 Million in Series B Venture Funding 56
Autonomic Technologies Secures US$32 Million In Series C Venture Financing 57
Atlas Genetics Raises US$27 Million In Series B Financing 58
Transcend Medical Secures Additional US$15 Million In Series B Venture Financing 60
MyoPowers Medical Secures US$18.9 Million In Series B Financing 62
Sorbent Therapeutics Secures An Additional US$36 Million In Series B Venture Financing 63
WaveTec Vision Secures US$15.9 Million In Series D Venture Financing Round 64
Wavetec Vision Raises US$3.5 Million In Venture Financing 65
Private Equity 66
dievini Hopp BioTech to Acquire Remaining Stake in LTS Lohmann Therapie-Systeme from Novartis and BWK 66
Partnerships 67
Alcon Enters into Licensing Agreement with Google for Smart Lens Technology 67
Klox Technologies Enters Into Licensing Agreement With Sandoz Canada 68
Camurus Exercises Option For Licensing Agreement With Novartis For Octreotide 69
IRIDEX Enters Into Licensing Agreement With Alcon 70
OctreoPharm Sciences Enters Into Licensing Agreement With Novartis Pharma For SOMscan 71
NuvoAir Enters into Agreement with Novartis 72
Propeller Health Enters into Agreement with Novartis Pharma 73
Lupin Enters into Co-Marketing Agreement with Novartis Healthcare 74
Novartis Enters into Agreement with Microsoft 75
MedinCell Enters into Agreement with Sandoz International 76
Thermo Fisher Scientific Enters into Agreement with Novartis and Pfizer 77
CorTechs Labs Enters into Agreement with Novartis Pharma 78
Qiagen Enters into Co-Development Agreement with Novartis 79
SomaLogic Extends Co-Development Agreement with Novartis 80
MolecularMD Enters Into Agreement With Novartis To Develop Companion Diagnostic Test For Chronic Myelogenous Leukemia 81
Foundation Medicine Extends Co-Development Agreement With Novartis 82
Grifols Enters Into Co-Marketing Agreement With Novartis 83
Foundation Medicine Enters Into An Agreement With Novartis 84
Foundation Medicine Expands Co-Development Agreement With Novartis 85
Sunovion Pharma Enters into Licensing Agreement with Novartis 86
Novartis Enters into Licensing Agreement with Abbott Vascular for Everolimus 87
Novartis Enters into Licensing Agreement with Boston Scientific for Everolimus 88
BioQuiddity Expands Licensing Agreement with Sandoz 89
Life Technologies Enters Into Licensing Agreement With Novartis 90
Themis Medicare Enters Into Licensing Agreement With Novartis India For Diclofenac Topical Gel 91
Debt Offering 92
Novartis Raises USD647.19 Million in Public Offering of International Bonds Due 2027 92
Novartis Raises USD1.3 Billion in Public Offering of International Bonds Due 2021 93
Novartis Raises USD561.78 Million in Public Offering of International Bonds Due 2028 94
Novartis Raises USD1.40 Billion in Public Offering of International Bonds Due 2023 95
Novartis Raises USD1.75 Billion in Public Offering of 3% Bonds Due 2025 96
Novartis Raises USD1.25 Billion in Public Offering of 4% Bonds Due 2045 97
Novartis Raises USD2.15 Billion in Public Offering of 3.4% Bonds Due 2024 98
Novartis Raises USD1.85 Billion in Public Offering of 4.4% Bonds Due 2044 99
Novartis Completes Public Offering Of 2.4% Senior Notes Due 2022 For US$1.5 Billion 100
Novartis Completes Public Offering Of 3.7% Senior Notes Due 2042 For US$500 Million 101
Asset Transactions 102
China NT Pharma to Acquire Miacalcic Injectable and Miacalcic Spray from Novartis for USD145 Million 102
Novartis Plans to Divest Assets of Alcon 103
Grifols Acquires Blood Transfusion Diagnostics Business from Novartis for USD1.66 Billion 104
Acquisition 106
Novartis to Acquire Advanced Accelerator Applications for USD3.9 Billion 106
United Therapeutics May Sell Itself 108
GlaxoSmithKline May Acquire Remaining 36.5% Stake in GlaxoSmithKline Consumer Healthcare from Novartis for USD10.3 Billion 109
Johnson & Johnson, Novartis and Takeda Pharma May Acquire Hypermarcas 110
Alcon Acquires Transcend Medical 112
Novartis May Acquire Genfit 113
Novartis Acquires Ziarco Group 114
Novartis Acquires Encore Vision 115
Alcon Acquires WaveTec Vision Systems 116
Novartis Acquires Vivacta For US$90 Million 118
Alcon Acquires Endure Medical Systems, Technology Surgical Microscopes Provider 119
Novartis Completes Acquisition Of Remaining 23% Stake In Alcon 120
Novartis AG – Key Competitors 122
Novartis AG – Key Employees 123
Novartis AG – Locations And Subsidiaries 124
Head Office 124
Other Locations & Subsidiaries 124
Recent Developments 141
Strategy And Business Planning 141
May 25, 2016: Novartis highlights its strong foundation for long-term, sustainable growth at the third Meet Novartis Management event 141
Financial Announcements 143
Oct 24, 2017: Novartis delivered growth on top and bottom line in all divisions in Q3 143
Jul 18, 2017: Q2 results confirm full year guidance. Strong pipeline results underpin potential of several highly innovative products 148
Apr 25, 2017: Novartis delivered sales growth across all divisions as growth drivers, including Cosentyx and Entresto, more than offset generic erosion; innovation momentum continued 153
Jan 25, 2017: Novartis delivered solid 2016 performance, with Growth Products absorbing Gleevec US LOE; innovation momentum continued; announces share buyback 157
Oct 25, 2016: Novartis delivered solid third quarter with Growth Products offsetting Gleevec patent expiration; several positive readouts for potential blockbusters 163
Jul 19, 2016: Novartis delivered solid Q2 despite full quarter of US Gleevec generic impact; significant positive innovation news strengthens future growth prospects 169
Apr 21, 2016: Novartis delivered solid Q1 despite Gleevec loss of exclusivity; investing behind new launches for long-term growth 175
Jan 27, 2016: Novartis delivered strong sales growth and core margin expansion (cc[1]) in 2015; announces plans to accelerate growth at Alcon, streamline Group operations 180
Corporate Communications 188
Dec 15, 2017: Novartis announces Oncology head to retire 188
Sep 04, 2017: Novartis announces CEO Joseph Jimenez to retire from Novartis in 2018. Vasant Narasimhan appointed CEO, effective February 1, 2018. 189
Aug 24, 2017: Novartis appoints Bertrand Bodson as Chief Digital Officer 190
May 08, 2017: Dr. Stephen S. Lane joins Alcon as Chief Medical Officer and Global Head Franchise Clinical Strategy 191
Feb 28, 2017: Novartis shareholders approve all resolutions proposed by Board of Directors at the Annual General Meeting 192
Product News 193
Jun 06, 2017: Alcon highlights product and service innovations at 40th BCLA, one of the largest international meetings dedicated to contact lenses 193
Jul 01, 2016: Alcon showcases latest innovations – first and only water gradient multifocal contact lenses, its differentiated portfolio, and innovative partnerships – at the 2016 Optometry’s Meeting 195
Apr 20, 2016: Alcon launches CLEAR CARE Rinse & Go for quick, gentle contact lens rinsing at home or on the go 197
Other Significant Developments 198
Sep 29, 2017: Alcon flagship AcrySof intraocular lens reaches 100 million implants and counting 198
Jun 05, 2017: Novartis announces ground-breaking collaboration with IBM Watson Health on outcomes-based care in advanced breast cancer 199
Mar 16, 2017: Alcon and Orbis celebrate new Flying Eye Hospital’s visit to the UK 200
Mar 03, 2017: Alcon Launches New Digital Vision Care Marketing Portal for Eye Care Professionals 201
Mar 02, 2017: Alcon Supports Eye Health with Charitable Giving of Nearly $73 Million in 2016 and Renews Commitment to Think About Your Eyes 202
Jan 26, 2017: Novartis highlights progress towards access and environmental goals in 2016 Corporate Responsibility Performance Report 203
Jan 26, 2017: Achievement of sales milestone for COPD products 204
Jan 25, 2017: Seebri / Ultibro Breezhaler 2016 sales reach $512 million triggering $5 million milestone receipt 205
Nov 29, 2016: Novartis Access shares one-year learnings and announces memorandum of understanding with Rwanda 206
Aug 15, 2016: Alcon’s new online Toric IOL Calculator offers best-in-class way to optimize outcomes for cataract/astigmatism patients 207
May 24, 2016: COTA Increases Cross-Industry Support With the Addition of Celgene, Foundation Medicine HealthScape Advisors and Novartis as Strategic Investors 208
May 17, 2016: Novartis focuses Pharmaceuticals Division by creating two business units, Novartis Pharmaceuticals and Novartis Oncology; appoints leaders to the Executive Committee of Novartis 209
Mar 31, 2016: Novartis publishes updated 2015 segment financials reflecting new division structure 210
Appendix 211
Methodology 211
About GlobalData 211
Contact Us 211
Disclaimer 211

List of Tables
Novartis AG, Medical Equipment, Key Facts, 2016 2
Novartis AG, Medical Equipment, Deals Summary, 2011 to YTD 2017 2
Novartis AG, Medical Equipment, Deals By Year, 2011 to YTD 2017 10
Novartis AG, Medical Equipment Deals By Type, 2011 to YTD 2017 11
Novartis AG, Medical Equipment, Deals By Region, 2011 to YTD 2017 12
Novartis AG, Deals By Market, 2011 to YTD 2017 13
Novartis AG, Medical Equipment, Deals Summary, 2011 to YTD 2017 14
ImaginAb Raises USD7.7 Million in Venture Financing 22
Rani Therapeutics Raises USD39 Million in Series D Financing 23
Lemonaid Health Raises USD11 Million in Series A Financing 24
Atlas Genetics Raises USD35 Million in Series D Financing 25
Seventh Sense Biosystems Raises USD10 Million in Series C Financing 27
Rox Medical Raises USD40 Million in Series E Financing 29
Cota Raises Funds through Venture Financing 30
Ra Pharma Raises USD58.5 Million in Series B Financing 31
Autonomic Technologies Raises Additional USD5.5 Million in Series D Financing 32
MyoPowers Medical Raises USD5 Million in Venture Financing 34
Autonomic Technologies Raises USD38 Million in Series D Financing 35
Merganser Biotech Raises USD28 Million in Series A Financing 37
Encore Vision Raises USD1 Million in Venture Financing 38
Atlas Genetics Raises USD20 Million in Series C Financing 39
Transcend Medical Raises USD7.2 Million in Venture Financing 41
BioNano Genomics Raises USD53 Million in Series C Venture Financing 42
Seventh Sense Biosystems Raises USD16 Million in Series B Financing 43
ImaginAb Raises US$21 Million In Series B Venture Financing 45
Transcend Medical Raises US$22 Million In Series C Venture Financing 46
Wavetec Vision Systems Raises US$0.8 Million In Venture Financing 47
Encore Vision Secures USD5 Million in Venture Funding 48
Wavetec Vision Raises US$11 Million In Series D-2 Financing 49
Proteus Digital Health Raises US$63 Million In Series F Financing Round 50
Health XL Raises Funds Through Venture Financing 51
Wavetec Vision Raises US$16.5 Million In Venture Financing 52
Advanced Animal Diagnostics Secures USD4 Million in Second Tranche of Series B Funding 53
ImaginAb Raises US$12.5 Million In Series A Financing 54
WaveTec Vision Raises US$1.5 Million In Venture Financing 55
Transcend Medical Secures USD16 Million in Series B Venture Funding 56
Autonomic Technologies Secures US$32 Million In Series C Venture Financing 57
Atlas Genetics Raises US$27 Million In Series B Financing 58
Transcend Medical Secures Additional US$15 Million In Series B Venture Financing 60
MyoPowers Medical Secures US$18.9 Million In Series B Financing 62
Sorbent Therapeutics Secures An Additional US$36 Million In Series B Venture Financing 63
WaveTec Vision Secures US$15.9 Million In Series D Venture Financing Round 64
Wavetec Vision Raises US$3.5 Million In Venture Financing 65
dievini Hopp BioTech to Acquire Remaining Stake in LTS Lohmann Therapie-Systeme from Novartis and BWK 66
Alcon Enters into Licensing Agreement with Google for Smart Lens Technology 67
Klox Technologies Enters Into Licensing Agreement With Sandoz Canada 68
Camurus Exercises Option For Licensing Agreement With Novartis For Octreotide 69
IRIDEX Enters Into Licensing Agreement With Alcon 70
OctreoPharm Sciences Enters Into Licensing Agreement With Novartis Pharma For SOMscan 71
NuvoAir Enters into Agreement with Novartis 72
Propeller Health Enters into Agreement with Novartis Pharma 73
Lupin Enters into Co-Marketing Agreement with Novartis Healthcare 74
Novartis Enters into Agreement with Microsoft 75
MedinCell Enters into Agreement with Sandoz International 76
Thermo Fisher Scientific Enters into Agreement with Novartis and Pfizer 77
CorTechs Labs Enters into Agreement with Novartis Pharma 78
Qiagen Enters into Co-Development Agreement with Novartis 79
SomaLogic Extends Co-Development Agreement with Novartis 80
MolecularMD Enters Into Agreement With Novartis To Develop Companion Diagnostic Test For Chronic Myelogenous Leukemia 81
Foundation Medicine Extends Co-Development Agreement With Novartis 82
Grifols Enters Into Co-Marketing Agreement With Novartis 83
Foundation Medicine Enters Into An Agreement With Novartis 84
Foundation Medicine Expands Co-Development Agreement With Novartis 85
Sunovion Pharma Enters into Licensing Agreement with Novartis 86
Novartis Enters into Licensing Agreement with Abbott Vascular for Everolimus 87
Novartis Enters into Licensing Agreement with Boston Scientific for Everolimus 88
BioQuiddity Expands Licensing Agreement with Sandoz 89
Life Technologies Enters Into Licensing Agreement With Novartis 90
Themis Medicare Enters Into Licensing Agreement With Novartis India For Diclofenac Topical Gel 91
Novartis Raises USD647.19 Million in Public Offering of International Bonds Due 2027 92
Novartis Raises USD1.3 Billion in Public Offering of International Bonds Due 2021 93
Novartis Raises USD561.78 Million in Public Offering of International Bonds Due 2028 94
Novartis Raises USD1.40 Billion in Public Offering of International Bonds Due 2023 95
Novartis Raises USD1.75 Billion in Public Offering of 3% Bonds Due 2025 96
Novartis Raises USD1.25 Billion in Public Offering of 4% Bonds Due 2045 97
Novartis Raises USD2.15 Billion in Public Offering of 3.4% Bonds Due 2024 98
Novartis Raises USD1.85 Billion in Public Offering of 4.4% Bonds Due 2044 99
Novartis Completes Public Offering Of 2.4% Senior Notes Due 2022 For US$1.5 Billion 100
Novartis Completes Public Offering Of 3.7% Senior Notes Due 2042 For US$500 Million 101
China NT Pharma to Acquire Miacalcic Injectable and Miacalcic Spray from Novartis for USD145 Million 102
Novartis Plans to Divest Assets of Alcon 103
Grifols Acquires Blood Transfusion Diagnostics Business from Novartis for USD1.66 Billion 104
Novartis to Acquire Advanced Accelerator Applications for USD3.9 Billion 106
United Therapeutics May Sell Itself 108
GlaxoSmithKline May Acquire Remaining 36.5% Stake in GlaxoSmithKline Consumer Healthcare from Novartis for USD10.3 Billion 109
Johnson & Johnson, Novartis and Takeda Pharma May Acquire Hypermarcas 110
Alcon Acquires Transcend Medical 112
Novartis May Acquire Genfit 113
Novartis Acquires Ziarco Group 114
Novartis Acquires Encore Vision 115
Alcon Acquires WaveTec Vision Systems 116
Novartis Acquires Vivacta For US$90 Million 118
Alcon Acquires Endure Medical Systems, Technology Surgical Microscopes Provider 119
Novartis Completes Acquisition Of Remaining 23% Stake In Alcon 120
Novartis AG, Key Competitors 122
Novartis AG, Key Employees 123
Novartis AG, Subsidiaries 124

★海外企業調査レポート[Novartis AG (NOVN)-医療機器分野：企業M&A・提携分析]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • DCO Energy LLC-エネルギー分野：企業M&A・提携分析
    Summary DCO Energy LLC (DCO) is an energy development company that constructs, operates, develops, and maintains cogeneration and renewable energy projects across the US. The company's services include financing, performance testing, equipment and systems analyses, retro-commissioning services, ener …
  • GIZEH Raucherbedarf GmbH：企業の戦略的SWOT分析
    GIZEH Raucherbedarf GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • The Centre of Excellence for Prevention of Organ Failure：医療機器：M&Aディール及び事業提携情報
    Summary The Centre of Excellence for Prevention of Organ Failure (PROOF Centre) is a healthcare center that provides blood-based biomarker tests. The center conducts biomarker programs to develop simple blood tests for transplant patients and patients with chronic organ disease and biomarkers in tra …
  • Relief Therapeutics Holding AG (RLF)：製薬・医療：M&Aディール及び事業提携情報
    Summary Relief Therapeutics Holding AG (Relief Therapeutics) is a drug development company that offers clinical development of peptides and proteins of natural or engineered origin. The company’s pipeline drug candidates include aviptadil for the treatment of sarcoidosis and low dose interleukin-6 t …
  • Clay Electric Cooperative, Inc.：企業の戦略的SWOT分析
    Clay Electric Cooperative, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pro …
  • Mercer International Inc (MERC)：企業の財務・戦略的SWOT分析
    Mercer International Inc (MERC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Sinopac Financial Holdings Company Limited：企業の戦略・SWOT・財務分析
    Sinopac Financial Holdings Company Limited - Strategy, SWOT and Corporate Finance Report Summary Sinopac Financial Holdings Company Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, …
  • Banca Sella Holding SpA：企業の戦略的SWOT分析
    Banca Sella Holding SpA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • Public Broadcasting Service：企業の戦略・SWOT・財務情報
    Public Broadcasting Service - Strategy, SWOT and Corporate Finance Report Summary Public Broadcasting Service - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • NanoRepro AG (NN6)：製薬・医療：M&Aディール及び事業提携情報
    Summary NanoRepro AG (NanoRepro) is a manufacturer of fast-diagnostics and nutritional food supplements for home and clinical use. The company offers wide range of rapid diagnostic tests products in the areas of family planning, disease detection (preventive healthcare), food intolerances, allergies …
  • Berry Global Group, Inc.：企業のM&A・事業提携・投資動向
    Berry Global Group, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Berry Global Group, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisiti …
  • Taisei Corporation：企業の戦略・SWOT・財務情報
    Taisei Corporation - Strategy, SWOT and Corporate Finance Report Summary Taisei Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Tyler Technologies Inc (TYL)：企業の財務・戦略的SWOT分析
    Tyler Technologies Inc (TYL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Centrexion Therapeutics Corp：製薬・医療：M&Aディール及び事業提携情報
    Summary Centrexion Therapeutics Corp (Centrexion Therapeutics), formerly Centrexion Corp is a developer of clinical pipelines of novel and non opioid chronic pain therapy products. The company offers products such as CNTX-4975, CNTX- 0290, CNTX-6970, CNTX-2022, CNTX-6016 and Intrathecalplatform. Its …
  • Zebra Technologies Corp (ZBRA)：企業の財務・戦略的SWOT分析
    Zebra Technologies Corp (ZBRA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Maxim Integrated Products, Inc.：企業の戦略・SWOT・財務情報
    Maxim Integrated Products, Inc. - Strategy, SWOT and Corporate Finance Report Summary Maxim Integrated Products, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Rentokil Initial plc (RTO)：企業の財務・戦略的SWOT分析
    Rentokil Initial plc (RTO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Care Group：企業の製品パイプライン分析2018
    Summary Care Group India (Care Group) is a manufacturer and supplier of intraocular lens (IOLs) and ophthalmic surgical products. Its product portfolio includes cataract intraocular lens (IOLs) including hydrophilic, hydrophobic, polymethyl methacrylate (PMMA) models and implantable phakic contact l …
  • SMA Solar Technology AG (S92)-エネルギー分野：企業M&A・提携分析
    Summary SMA Solar Technology AG (SMA) is a renewable energy company that develops, produces, and distributes photovoltaic (PV) inverters, transformers, choke coils, and monitoring and energy management systems for PV systems. It also offers operation and maintenance services for photovoltaic power p …
  • Cummins Inc (CMI)：電力：M&Aディール及び事業提携情報
    Summary Cummins Inc. (Cummins), formerly Cummins Engine Company, is a manufacturer of diesel engines and related technologies. It designs, manufactures, services and distributes engines and related component solutions. The company offers filtration, fuel systems, control systems, after treatment dev …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆